Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas

Pancreas. 2003 Nov;27(4):e84-9. doi: 10.1097/00006676-200311000-00019.

Abstract

Objectives: Five distinct somatostatin receptors (SSTRs) have been cloned, characterized, and designated SSTRs 1-5. The role of these receptors in B-cell signaling has not been well characterized.

Methods: In the current study, the isolated perfused human pancreas model was used to determine the specific effect of 4 different somatostatin receptor agonists on insulin secretion.

Conclusion: We demonstrated that the SSTR 2 agonist and octreotide significantly suppressed insulin secretion. Furthermore, even during the immunoneutralization of endogenous intrapancreatic somatostatin, the SSTR 2 agonist was able to reverse the effect of somatostatin immunoneutralization by suppressing insulin secretion. These results demonstrate that activation of SSTR 2 suppresses insulin secretion in the isolated perfused human pancreas.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal / pharmacology
  • Cadaver
  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Immunoglobulin Fab Fragments / pharmacology
  • In Vitro Techniques
  • Insulin / metabolism*
  • Insulin Secretion
  • Male
  • Middle Aged
  • Octreotide / pharmacology
  • Pancreas / drug effects
  • Pancreas / metabolism*
  • Perfusion
  • Receptors, Somatostatin / agonists
  • Receptors, Somatostatin / immunology
  • Receptors, Somatostatin / physiology*
  • Somatostatin / analogs & derivatives*
  • Somatostatin / pharmacology

Substances

  • Antibodies, Monoclonal
  • DC 32-87
  • Immunoglobulin Fab Fragments
  • Insulin
  • Receptors, Somatostatin
  • Somatostatin
  • somatostatin receptor 2
  • Octreotide